Odyssey Therapeutics, Inc. Common Stock (ODTX) - Net Assets
Based on the latest financial reports, Odyssey Therapeutics, Inc. Common Stock (ODTX) has net assets worth $421.22 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($483.85 Million) and total liabilities ($62.63 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. See Odyssey Therapeutics, Inc. Common Stock net asset quality index to measure how much of total assets are equity-financed.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $421.22 Million |
| % of Total Assets | 87.06% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Odyssey Therapeutics, Inc. Common Stock - Net Assets Trend (2022–2025)
This chart illustrates how Odyssey Therapeutics, Inc. Common Stock's net assets have evolved over time, based on quarterly financial data. Also explore ODTX shareholders equity momentum to track the company's year-over-year net asset growth rate.
Annual Net Assets for Odyssey Therapeutics, Inc. Common Stock (2022–2025)
The table below shows the annual net assets of Odyssey Therapeutics, Inc. Common Stock from 2022 to 2025. For live market cap and overall valuation, see Odyssey Therapeutics, Inc. Common Stock (ODTX) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-488.28 Million | -27.65% |
| 2024-12-31 | $-382.53 Million | -45.61% |
| 2023-12-31 | $-262.71 Million | -81.65% |
| 2022-12-31 | $-144.62 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Odyssey Therapeutics, Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 40996800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Comprehensive Income | $245.00K | % |
| Other Components | $79.62 Million | % |
| Total Equity | $-488.28 Million | 100.00% |
Odyssey Therapeutics, Inc. Common Stock Competitors by Market Cap
The table below lists competitors of Odyssey Therapeutics, Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
KBC Corporation Ltd
SHG:688598
|
$870.84 Million |
|
Plazza AG
SW:PLAN
|
$871.47 Million |
|
Creades AB
ST:CRED-A
|
$871.69 Million |
|
Southside Bancshares, Inc.
NASDAQ:SBSI
|
$871.72 Million |
|
Guanghui Logistics Co Ltd
SHG:600603
|
$870.71 Million |
|
Hangzhou Weiguang Electronic Co Ltd
SHE:002801
|
$870.64 Million |
|
Simply Good Foods Co
NASDAQ:SMPL
|
$870.26 Million |
|
Wuhan Zhongyuan Huadian Sci Tech
SHE:300018
|
$869.99 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Odyssey Therapeutics, Inc. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -382,527,000 to -488,278,000, a change of -105,751,000.
- Net loss of 148,647,000 reduced equity.
- New share issuances of 212,458,000 increased equity.
- Other comprehensive income increased equity by 245,000.
- Other factors decreased equity by 169,807,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-148.65 Million | -30.44% |
| Share Issuances | $212.46 Million | +43.51% |
| Other Comprehensive Income | $245.00K | +0.05% |
| Other Changes | $-169.81 Million | -34.78% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Odyssey Therapeutics, Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-12-31 | $-3.07 | $19.00 | x |
| 2023-12-31 | $-5.57 | $19.00 | x |
| 2024-12-31 | $-8.11 | $19.00 | x |
| 2025-12-31 | $-17.72 | $19.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Odyssey Therapeutics, Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -4994.86%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is below the historical average (0.00%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-110.20 Million |
| 2023 | 0.00% | -12144.46% | 0.00x | 0.00x | $-99.67 Million |
| 2024 | 0.00% | -2891.79% | 0.02x | 0.00x | $-91.07 Million |
| 2025 | 0.00% | -4994.86% | 0.01x | 0.00x | $-99.82 Million |
Industry Comparison
This section compares Odyssey Therapeutics, Inc. Common Stock's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $196,543,967
- Average return on equity (ROE) among peers: -37.76%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Odyssey Therapeutics, Inc. Common Stock (ODTX) | $421.22 Million | 0.00% | 0.15x | $870.82 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $103.64 Million |
| Abcellera Biologics Inc (ABCL) | $1.23 Billion | 12.85% | 0.25x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $159.22 Million | 44.71% | 0.38x | $282.49 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $70.43 Million | -172.28% | 0.74x | $154.57 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $366.11 Million | -27.58% | 0.16x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $106.02 Million | -68.71% | 0.36x | $836.01 Million |
| ABVC Biopharma Inc (ABVC) | $60.67K | -43.96% | 0.04x | $26.65 Million |
| Abivax SA American Depositary Shares (ABVX) | $56.72 Million | -25.23% | 0.07x | $7.69 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.41 Billion |
About Odyssey Therapeutics, Inc. Common Stock
Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company pipeline includes OD-001, an oral small molecule inhibitor of receptor-interacting protein kinase 2, which is in phase 2a trial for the treatment of ulcerative colitis; OD-002, an oral small molecule SLC15A4 inhibitor designed to block TLR7/8/9-mediated … Read more